metformin has been researched along with Pancreatitis in 29 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In people with metformin-treated diabetes, to evaluate the risk of acute pancreatitis, pancreatic cancer and other diseases of the pancreas post second-line anti-hyperglycaemic agent initiation." | 7.91 | Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. ( Atherton, J; Green, JB; Montvida, O; Paul, SK, 2019) |
| "We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme." | 7.80 | A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. ( Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K, 2014) |
| "Metformin use in diabetes can cause acidosis and might be linked to pancreatitis." | 7.76 | Metformin treatment of diabetes mellitus increases the risk for pancreatitis in patients bearing the CFTR-mutation S573C. ( Cassidy, D; Kongsuphol, P; Kunzelmann, K; Mehta, A; Romeiras, F; Schreiber, R, 2010) |
| "To estimate risk and relative risk (RR) of acute pancreatitis among patients using incretin-based diabetes therapies (exenatide or sitagliptin) compared to patients treated with agents with established safety profiles (metformin or glyburide)." | 7.75 | Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. ( Arnold Chan, K; Dore, DD; Seeger, JD, 2009) |
| "An 82-year-old woman with type 2 diabetes mellitus, hypertension, and unstable angina presented with severe lactic acidosis and acute kidney injury (AKI) accompanied by acute pancreatitis." | 5.39 | Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. ( Ahn, KS; Hong, CW; Kang, GW; Lee, DY; Lee, IH; Seo, JH, 2013) |
| "Byetta was withdrawn, the patient was treated for acute pancreatitis and the symptoms subsided." | 5.35 | Exenatide and acute pancreatitis. ( Basha, S; Jain, R; Ramachandran, A; Shetty, S; Tripathy, NR, 2008) |
| "Metformin is a biguanide commonly used in type 2 diabetes and considered to be a safe drug with minimal side effects." | 5.32 | Metformin induced acute pancreatitis precipitated by renal failure. ( Mallick, S, 2004) |
| "In people with metformin-treated diabetes, to evaluate the risk of acute pancreatitis, pancreatic cancer and other diseases of the pancreas post second-line anti-hyperglycaemic agent initiation." | 3.91 | Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. ( Atherton, J; Green, JB; Montvida, O; Paul, SK, 2019) |
| "To examine the relationship between different anti-diabetic therapies (dipeptidyl peptidase-4 (DPP-4), metformin and sulfonylureas) and risk of acute pancreatitis among type 2 diabetic patients in Taiwan, and explore each drug's dose-response relationship." | 3.81 | Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. ( Chang, HY; Chiang, YT; Hsieh, CF; Huang, WF; Singh, S; Tang, W, 2015) |
| "We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme." | 3.80 | A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. ( Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K, 2014) |
| "Metformin use in diabetes can cause acidosis and might be linked to pancreatitis." | 3.76 | Metformin treatment of diabetes mellitus increases the risk for pancreatitis in patients bearing the CFTR-mutation S573C. ( Cassidy, D; Kongsuphol, P; Kunzelmann, K; Mehta, A; Romeiras, F; Schreiber, R, 2010) |
| "To estimate risk and relative risk (RR) of acute pancreatitis among patients using incretin-based diabetes therapies (exenatide or sitagliptin) compared to patients treated with agents with established safety profiles (metformin or glyburide)." | 3.75 | Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. ( Arnold Chan, K; Dore, DD; Seeger, JD, 2009) |
| " The overall frequency of adverse events was similar among the groups." | 2.84 | Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. ( Kaku, K; Katou, M; Kinugawa, Y; Nishiyama, Y; Sumino, S, 2017) |
| " Secondary outcomes were non-cardiovascular adverse events." | 2.82 | Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. ( Chong, CW; Fong, AYY; Hussein, Z; Khunti, K; Lee, SWH; Loganadan, NK; Navaravong, L; Sim, R, 2022) |
| "Vildagliptin is an effective and safe therapeutic option for patients with T2DM, both as monotherapy and as add-on treatment." | 2.53 | Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. ( Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Rika, M; Rizava, C; Tsapas, A, 2016) |
| "Metformin promotes a survival benefit in individuals with PPDM but not PCRD." | 1.51 | Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. ( Cho, J; Goodarzi, MO; Pandol, SJ; Petrov, MS; Scragg, R, 2019) |
| "To assess the risk of acute pancreatitis during treatment with glucagon-like peptide 1 receptor agonist dulaglutide, placebo, and active comparators across phase 2/3 dulaglutide trials." | 1.46 | Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. ( Anglin, G; Barkin, JS; Frossard, JL; Harper, KD; Hensley, IE; Milicevic, Z; Nauck, MA, 2017) |
| "Metformin treatment alone or with sitagliptin decreased islet amyloid deposition to a similar extent vs untreated mice." | 1.39 | One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. ( Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S, 2013) |
| "An 82-year-old woman with type 2 diabetes mellitus, hypertension, and unstable angina presented with severe lactic acidosis and acute kidney injury (AKI) accompanied by acute pancreatitis." | 1.39 | Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. ( Ahn, KS; Hong, CW; Kang, GW; Lee, DY; Lee, IH; Seo, JH, 2013) |
| "Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity." | 1.38 | Diabetes and pancreatic cancer. ( Li, D, 2012) |
| "Byetta was withdrawn, the patient was treated for acute pancreatitis and the symptoms subsided." | 1.35 | Exenatide and acute pancreatitis. ( Basha, S; Jain, R; Ramachandran, A; Shetty, S; Tripathy, NR, 2008) |
| "Metformin is a biguanide commonly used in type 2 diabetes and considered to be a safe drug with minimal side effects." | 1.32 | Metformin induced acute pancreatitis precipitated by renal failure. ( Mallick, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 19 (65.52) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Sim, R | 1 |
| Chong, CW | 1 |
| Loganadan, NK | 1 |
| Fong, AYY | 1 |
| Navaravong, L | 1 |
| Hussein, Z | 1 |
| Khunti, K | 1 |
| Lee, SWH | 1 |
| Montvida, O | 1 |
| Green, JB | 1 |
| Atherton, J | 1 |
| Paul, SK | 1 |
| Cho, J | 1 |
| Scragg, R | 1 |
| Pandol, SJ | 1 |
| Goodarzi, MO | 1 |
| Petrov, MS | 1 |
| Mathuram Thiyagarajan, U | 1 |
| Ponnuswamy, A | 1 |
| Chung, A | 1 |
| Aston-Mourney, K | 1 |
| Subramanian, SL | 1 |
| Zraika, S | 1 |
| Samarasekera, T | 1 |
| Meier, DT | 1 |
| Goldstein, LC | 1 |
| Hull, RL | 1 |
| Kalantar-Zadeh, K | 1 |
| Uppot, RN | 1 |
| Lewandrowski, KB | 1 |
| Seo, JH | 1 |
| Lee, DY | 1 |
| Hong, CW | 1 |
| Lee, IH | 1 |
| Ahn, KS | 1 |
| Kang, GW | 1 |
| Funch, D | 1 |
| Gydesen, H | 1 |
| Tornøe, K | 1 |
| Major-Pedersen, A | 1 |
| Chan, KA | 1 |
| Del Prato, S | 1 |
| Camisasca, R | 1 |
| Wilson, C | 1 |
| Fleck, P | 1 |
| Chang, HY | 1 |
| Hsieh, CF | 1 |
| Singh, S | 1 |
| Tang, W | 1 |
| Chiang, YT | 1 |
| Huang, WF | 1 |
| Bekiari, E | 1 |
| Rizava, C | 1 |
| Athanasiadou, E | 1 |
| Papatheodorou, K | 1 |
| Liakos, A | 1 |
| Karagiannis, T | 1 |
| Mainou, M | 1 |
| Rika, M | 1 |
| Boura, P | 1 |
| Tsapas, A | 1 |
| McFadden, M | 1 |
| Gordon, A | 1 |
| Leong, G | 1 |
| Ward, D | 1 |
| Scott, JG | 1 |
| Taylor, SA | 1 |
| Himes, R | 1 |
| Hastings, E | 1 |
| Garland, B | 1 |
| Tinahones, FJ | 1 |
| Gallwitz, B | 1 |
| Nordaby, M | 1 |
| Götz, S | 1 |
| Maldonado-Lutomirsky, M | 1 |
| Woerle, HJ | 1 |
| Broedl, UC | 1 |
| Kaku, K | 1 |
| Sumino, S | 1 |
| Katou, M | 1 |
| Nishiyama, Y | 1 |
| Kinugawa, Y | 1 |
| Nauck, MA | 1 |
| Frossard, JL | 1 |
| Barkin, JS | 1 |
| Anglin, G | 1 |
| Hensley, IE | 1 |
| Harper, KD | 1 |
| Milicevic, Z | 1 |
| Molina Infante, J | 1 |
| Prieto Bermejo, AB | 1 |
| Pérez Gallardo, B | 1 |
| Fernández Bermejo, M | 1 |
| Dore, DD | 1 |
| Seeger, JD | 1 |
| Arnold Chan, K | 1 |
| Tripathy, NR | 1 |
| Basha, S | 1 |
| Jain, R | 1 |
| Shetty, S | 1 |
| Ramachandran, A | 1 |
| Kongsuphol, P | 1 |
| Cassidy, D | 1 |
| Romeiras, F | 1 |
| Schreiber, R | 1 |
| Mehta, A | 1 |
| Kunzelmann, K | 1 |
| Boehm, KM | 1 |
| Gunaga, S | 1 |
| Li, D | 1 |
| Gier, B | 1 |
| Matveyenko, AV | 1 |
| Kirakossian, D | 1 |
| Dawson, D | 1 |
| Dry, SM | 1 |
| Butler, PC | 1 |
| Bhasin, DK | 1 |
| Sidhu, RS | 1 |
| Bhansali, A | 1 |
| Nagi, B | 1 |
| Mallick, S | 1 |
| Fimognari, FL | 1 |
| Corsonello, A | 1 |
| Pastorell, R | 1 |
| Antonelli-Incalzi, R | 1 |
| Ortega Carnicer, J | 1 |
| Ambrós Checa, A | 1 |
| Diarte De Miguel, J | 1 |
| Audia, P | 1 |
| Feinfeld, DA | 1 |
| Dubrow, A | 1 |
| Winchester, JF | 1 |
| Ben, MH | 1 |
| Thabet, H | 1 |
| Zaghdoudi, I | 1 |
| Amamou, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Di[NCT01778049] | Phase 3 | 708 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change from baseline in Glycated haemoglobin (HbA1c) [%] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term baseline was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as pre-treatment. Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference.~Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial." (NCT01778049)
Timeframe: Baseline and 24 weeks
| Intervention | Percentage of HbA1c (Least Squares Mean) |
|---|---|
| Lina5 (E10) | -0.53 |
| Plc (E10) | -0.21 |
| Lina5 (E25) | -0.58 |
| Plc (E25) | -0.10 |
Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24. (NCT01778049)
Timeframe: Baseline and 24 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lina5 (E10) | -0.44 |
| Plc (E10) | 0.21 |
| Lina5 (E25) | -0.68 |
| Plc (E25) | -0.24 |
3 reviews available for metformin and Pancreatitis
| Article | Year |
|---|---|
Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypogl | 2022 |
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Met | 2016 |
Gastrointestinal Conditions in the Obese Patient.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Constipation; Contraceptiv | 2016 |
3 trials available for metformin and Pancreatitis
| Article | Year |
|---|---|
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2014 |
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2017 |
Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
Topics: Acute Disease; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administrat | 2017 |
23 other studies available for metformin and Pancreatitis
| Article | Year |
|---|---|
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Co | 2019 |
Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2019 |
An enigmatic triad of acute pancreatitis, diabetic ketoacidosis and hypertriglyceridaemia: who is the culprit?
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Fluid Therapy; Humans; Hydroxymethylglutary | 2019 |
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; H | 2013 |
Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion.
Topics: Abdominal Pain; Acidosis, Lactic; Confusion; Diabetes Mellitus, Type 2; Diagnosis, Differential; Fem | 2013 |
Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin.
Topics: Acidosis, Lactic; Aged, 80 and over; Cimetidine; Diabetes Mellitus, Type 2; Drug Interactions; Drug | 2013 |
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
Topics: Databases, Factual; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hyp | 2014 |
Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Topics: Adolescent; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2015 |
Pancreatitis associated with metformin used for management of clozapine-related weight gain.
Topics: Adolescent; Antipsychotic Agents; Clozapine; Disease Management; Humans; Male; Metformin; Pancreatit | 2016 |
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Gluca | 2017 |
[Toxic metformin-associated acute pancreatitis without kidney failure].
Topics: Acute Disease; Female; Humans; Hypoglycemic Agents; Metformin; Pancreatitis; Renal Insufficiency; Yo | 2008 |
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
Topics: Adolescent; Adult; Databases, Factual; Exenatide; Female; Glyburide; Humans; Hypoglycemic Agents; In | 2009 |
Exenatide and acute pancreatitis.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Drug Interactions; Exenatide; Female; Humans; Hypoglycemic | 2008 |
Metformin treatment of diabetes mellitus increases the risk for pancreatitis in patients bearing the CFTR-mutation S573C.
Topics: Amino Acid Substitution; Animals; Colforsin; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance R | 2010 |
Cimetidine-induced lactic acidosis and acute pancreatitis.
Topics: Acidosis, Lactic; Acute Disease; Cimetidine; Diabetes Mellitus, Type 2; Drug Interactions; Female; G | 2010 |
Diabetes and pancreatic cancer.
Topics: Adipokines; Diabetes Mellitus, Type 2; Early Detection of Cancer; Humans; Hypoglycemic Agents; Insul | 2012 |
Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
Topics: Animals; Exenatide; Glucagon-Like Peptide-1 Receptor; Homeodomain Proteins; Humans; Hypoglycemic Age | 2012 |
Diabetic ketoacidosis in a patient with chronic calcific pancreatitis after minor papilla stent insertion.
Topics: Alcoholism; Calcinosis; Cholangiopancreatography, Endoscopic Retrograde; Chronic Disease; Diabetic K | 2004 |
Metformin induced acute pancreatitis precipitated by renal failure.
Topics: Acidosis, Lactic; Acute Disease; Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Metformin-induced pancreatitis: A possible adverse drug effect during acute renal failure.
Topics: Acute Disease; Acute Kidney Injury; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Metformi | 2006 |
[Acute pancreatitis, acute kidney failure, metformin intoxication and villous rectal adenoma].
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenoma, Villous; Aged; Colonic Neoplasms; Colonoscopy; Diabe | 2006 |
Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction.
Topics: Acidosis, Lactic; Acute Disease; Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Benzi | 2008 |
Metformin associated acute pancreatitis.
Topics: Acute Disease; Adult; Amylases; Female; Humans; Hypoglycemic Agents; Lipase; Metformin; Pancreatitis | 2002 |